A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
Completed
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/02/2022
Locations: National Research Institute, Huntington Park, California +79 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
NCT02863328
Completed
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Tuscumbia, Alabama +105 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
NCT02863419
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +107 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
NCT02906930
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Lancaster, California +104 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
NCT02849080
Completed
This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Glendale, Arizona +82 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT02692716
Completed
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Little Rock, Arkansas +228 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
NCT02607865
Completed
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +241 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
NCT05220917
Unknown
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Cardiovascular Events, Type2 Diabetes, Renal Disease
Register for Updates
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT04287179
Withdrawn
This study compares the effect and safety of 2 dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide. The study will also evaluate the use of a new pen-injector for semaglutide used to inject medicine under the skin, at a new dose of 2 mg. People taking part in the study will take this medicine together with their current diabetes tablets other than semaglutide. Participants will either get a start dose o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2022
Locations: Novo Nordisk Investigational Site, Buena Park, California +24 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Cahaba Research, Birmingham, Alabama +126 locations
Conditions: Type 2 Diabetes
Register for Updates
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
NCT03086330
Completed
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2021
Locations: Novo Nordisk Investigational Site, Andalusia, Alabama +71 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT01923181
Completed
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2021
Locations: Novo Nordisk Investigational Site, Tucson, Arizona +102 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates